Agios Pharmaceuticals Inc’s recently made public that its Chief Medical Officer Gheuens Sarah unloaded Company’s shares for reported $0.45 million on Jul 09 ’25. In the deal valued at $37.99 per share,11,914 shares were sold. As a result of this transaction, Gheuens Sarah now holds 61,271 shares worth roughly $2.39 million.
Then, DAVID SCADDEN bought 1,400 shares, generating $56,000 in total proceeds.
Before that, SARAH GHEUENS bought 11,914 shares. Agios Pharmaceuticals Inc shares valued at $452,632 were divested by the Officer at a price of $37.99 per share.
H.C. Wainwright initiated its Agios Pharmaceuticals Inc [AGIO] rating to a Buy in a research note published on February 24, 2025; the price target was $58. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Leerink Partners revised its rating on September 27, 2024. It rated AGIO as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of AGIO
On Friday, Agios Pharmaceuticals Inc [NASDAQ:AGIO] saw its stock fall -1.21% to $39.05. Over the last five days, the stock has gained 8.26%. Agios Pharmaceuticals Inc shares have fallen nearly -8.55% since the year began. Nevertheless, the stocks have risen 18.84% over the past one year. While a 52-week high of $62.58 was reached on 07/10/25, a 52-week low of $23.42 was recorded on 04/09/25.
Levels Of Support And Resistance For AGIO Stock
The 24-hour chart illustrates a support level at 38.28, which if violated will result in even more drops to 37.50. On the upside, there is a resistance level at 39.87. A further resistance level may holdings at 40.68.
How much short interest is there in Agios Pharmaceuticals Inc?
A steep rise in short interest was recorded in Agios Pharmaceuticals Inc stocks on 2025-06-13, growing by 0.17 million shares to a total of 4.32 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 4.16 million shares. There was a rise of 3.83%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 08, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating .
